top of page
ADELA
PHASE III TRIAL RANDOMIZED TRIAL OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ER+/HER2- ESR-MUTATED ADVANCED BREAST CANCER REFRACTORY TO CDK4/6 INHIBITORS PLUS ENDOCRINE THERAPY
CLINICAL TRIAL DETAILS
A RANDOMIZED PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED, ADVANCED BREAST CANCER PROGRESSING TO ENDOCRINE THERAPY AND CDK4/6 INHIBITORS.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ER+/HER2- ABC
110
240
III
Austria, Brazil, Czech Republic, Spain, France, Greece, Italy, Germany, UK
Recruiting
TRIAL OVERVIEW
PRESS RELEASE
-
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
-
TRIAL SITES
-
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page